The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors

Haematologica. 2018 Apr;103(4):e169-e172. doi: 10.3324/haematol.2017.180166. Epub 2017 Dec 14.

Authors

Hanny Al-Samkari¹, Ariela L Marshall², Katayoon Goodarzi³, David J Kuter³

Affiliations

¹ Center for Hematology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA hal-samkari@mgh.harvard.edu.
² Division of Hematology, Mayo Clinic, Rochester, MN, USA.
³ Center for Hematology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents / adverse effects
Female
Humans
Male
Middle Aged
Neoplasms / complications*
Neoplasms / drug therapy
Receptors, Fc / therapeutic use*
Receptors, Thrombopoietin / agonists
Recombinant Fusion Proteins / therapeutic use*
Thrombocytopenia / chemically induced
Thrombocytopenia / drug therapy*
Thrombopoietin / therapeutic use*
Treatment Outcome
Young Adult

Substances

Antineoplastic Agents
Receptors, Fc
Receptors, Thrombopoietin
Recombinant Fusion Proteins
Thrombopoietin
romiplostim